Malignant peritoneal mesothelioma

This phase 2 trial is testing whether adding the immunotherapy drug atezolizumab to standard chemotherapy (carboplatin, pemetrexed, and bevacizumab) works better than chemotherapy alone for peritoneal mesothelioma, a rare cancer of the abdominal lining. About 66 people will take …

This phase 2 trial tests whether giving chemotherapy directly into the abdomen (intraperitoneal) or into a vein (intravenous) after surgery and heated chemotherapy works better for people with malignant peritoneal mesothelioma. Participants must have had successful removal of vis…

This study tests a new way to choose cancer treatments for people with peritoneal mesothelioma. After surgery, doctors will grow a model of the patient's tumor in the lab and test different drugs on it to find the best match. The goal is to see if this personalized approach helps…

This early-phase study tests a new drug called CT-95 in people with advanced cancers that have a protein called mesothelin on their cells. The main goals are to find a safe dose and see if the drug can shrink tumors. About 70 adults with ovarian, lung, pancreatic, or other mesoth…

This early-phase trial tests a new treatment for people with mesothelioma that cannot be removed by surgery or has come back after standard therapy. The treatment uses donor immune cells (natural killer cells) that are engineered in a lab to recognize and attack two proteins foun…

This study looks at a treatment called HIPEC, where heated chemotherapy is washed inside the abdomen after surgery to remove tumors. Researchers want to see if lab-grown tumor models can predict how well the chemotherapy works. Sixty adults with cancers that have spread to the ab…